RainMed’s caFFR will be exhibited at the offline exhibition of High Tech Cardio in Palais du Pharo, Marseille, France From February 1^st to 3^rd , 2023. High Tech is a professional congress gathering top interventional cardiology experts from France and the European Society of Cardiology to share cutting-edge technologies and clinical treatment research of interventional cardiology. It attracts top European experts and scholars, as well as major medical device enterprises on interventional cardiology treatment every year.

At last year's exhibition, senior French distributors with more than 10 years of Abbott sales experience conducted in-depth communication with guests from all over Europe on the highlights of RainMed’s caFFR with great confidence, and demonstrated the operation process of caFFR on site, which was highly praised by experts from all over the world. Participants highly praised caFFR as the pearl of oriental innovative medical devices and the Chinese original FFR product that can rival Abbott's guide wire-derived FFR. The achievements made by RainMed Medical in the field of innovation are constantly pushing domestic medical devices to the center of the international stage and leading the upsurge of overseas commercialization of China's original technologies. Hopefully, this year's exhibition will also be a grand event of technical exchange.

caFFR calculates fractional flow reserve FFR based on two angiograms without pressure guide wire or hyperemic agents. It can provide functional indicators during surgery to accurately evaluate whether coronary artery stenosis induces myocardial ischemia. It provides a safe, efficient, accurate and simple solution for cardiovascular diagnosis. Currently, caFFR has been successfully used in Germany, France, Austria, Czech Republic, Ireland, Serbia, Slovenia, South Africa and other countries. Designed and produced by a Chinese local team, caFFR will further demonstrate the infinite charm of China’s smart manufacturing on the global stage for hospitals and medical imaging centers at all levels.

In addition to the large-scale commercialization of caFFR, the caIMR system, another product of RainMed Medical, has recently triggered a frenzy of scientific research at home and abroad, gaining widespread attention and expectation from clinicians. As the world's first non-interventional microcirculation diagnostic product to enter clinical trials, caIMR is expected to become the world's first commercialized innovative microcirculation diagnostic method.

Studies confirmed that the combination of caFFR and caIMR can provide a complete functional evaluation of blood vessels from epicardial coronary arteries to intramyocardial microcirculation. In the future, caIMR system will combine with caFFR system, which is an important part of functional diagnosis module and will be integrated on FlashBot vascular interventional surgery robot. It will build an integrated solution of cathlab diagnosis and treatment, and contribute Chinese wisdom to promoting precise coronary diagnosis and treatment.

RainMed’s vascular interventional surgery robot will also be launched in the near future. The clinical application of this product will reduce the learning process of doctors, improve the level of homogenization of medical treatment, and enable patients with cardiovascular disease  nationwide and even globally to enjoy high-quality coronary interventional diagnosis and treatment services. The global commercial landing of vascular interventional surgical robots will further demonstrate its infinite charm of Chinese intelligence on the global stage.